By Fineline Cube 
US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with China-based 3SBio Inc., (HKG: 1530), securing development, manufacturing, and commercialization rights to SSGJ-707, a bispecific antibody (BsAb) targeting PD-1 and VEGF, for all markets excluding China.
Financial Terms
Under the agreement, 3SBio will receive an upfront payment of USD 1.25 billion. Additionally, 3SBio is eligible to receive milestone payments totaling up to USD 4.8 billion, contingent on achieving certain development, regulatory, and commercial milestones. The deal also includes provisions for tiered double-digit royalties.
Clinical Development
SSGJ-707 is currently undergoing multiple clinical studies in China, focusing on non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. The drug has demonstrated significant anti-tumor activity and good safety profile, both as a monotherapy and in combination with other therapies. The first Phase III study is scheduled to commence in China in 2025.-Fineline Info & Tech